FDA approves Pfizer nasal spray for migraines that relieves symptoms in 15 MINUTES - and will be in pharmacies by June
By Caitlin Tilley, Health Reporter For Dailymail.ComUpdated 15:19 GMT10 Mar 2023
- Zavzpret works by blocking receptors which cause inflammation and head pain
- Touted as the 'Epipen of migraine', it will be available from July 2023
- People who suffer debilitating headaches have physical changes to their brains
Dr Kathleen Mullin, associate medical director at New England Institute for Neurology & Headache, said: 'Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works.
'As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly.'
Pfizer added Zavzpret and other migraine treatments, including Nurtec ODT, to it drugs portfolio through its $11.6 billion buyout of Biohaven Pharmaceutical last year.
Zavzpret will compete with other therapies from AbbVie Inc, Eli Lilly and Co, Amgen Inc and Teva Pharmaceutical.
Pfizer is hoping to gain a competitive edge with zavegepant's quicker speed of action than other migraine treatments. Biohaven has pitched it as the 'Epipen of migraine'.
The company previously forecast $6 billion in sales from migraine portfolio at their peak
https://www.dailymail.co.uk/health/...DA-approves-Pfizers-nasal-spray-migraine.html